- Glenmark Pharma reported a 72% year-over-year increase in net income, reaching 6.1 billion rupees, surpassing the estimated 3.84 billion rupees.
- The company’s revenue rose by 76% compared to the previous year, totaling 60.5 billion rupees, exceeding the projected 43.42 billion rupees.
- Total costs for Glenmark Pharma increased by 30% year-over-year, amounting to 38.9 billion rupees.
- In terms of market sentiment, the company received 9 buy ratings, 1 hold rating, and 1 sell rating from analysts.
Glenmark Pharmaceuticals on Smartkarma
Analyst coverage of Glenmark Pharmaceuticals on Smartkarma highlights the significant impact of the recent $700 million biotech licensing deal with AbbVie. Sudarshan Bhandari‘s report, titled “Glenmark’s R&D Leap: How a Large Biotech Licensing Deal with AbbVie Could Change Its Fortune,” underscores the transformative nature of this agreement. With Glenmark Pharma securing this deal, it not only unlocks $1.9 billion in potential proceeds but also solidifies India’s position as a burgeoning biotech hub. AbbVie gains global rights for key markets, while Glenmark retains access to Emerging Markets, paving the way for a net-cash company status, fueling R&D initiatives, and postponing the need for an IPO.
A look at Glenmark Pharmaceuticals Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores for Glenmark Pharmaceuticals, the company seems to have a promising long-term outlook. With a strong momentum score of 4, Glenmark appears to be gaining traction in the market and showing positive performance trends. Additionally, scoring a 3 in both growth and resilience suggests that the company is well-positioned for future expansion and can weather economic challenges efficiently.
Although the value and dividend scores are more moderate at 2 each, indicating room for improvement in these areas, Glenmark Pharmaceuticals Ltd., as a pharmaceutical company focusing on generic drugs for inflammation, metabolic disorders, and pain, presents itself as a player with growth potential and a solid foundation for long-term success.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
